Home > Insider Trading > Filing (0001209191-20-018258)

Filing Details

Accession Number:: 0001209191-20-018258
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-11 19:07:19
Reporting Period:: 2020-03-09

Accepted Time:: 2020-03-11 19:07:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1503802	Karyopharm Therapeutics Inc.	KPTI	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1364719	Michael Kauffman	C/O Karyopharm Therapeutics Inc. 85 Wells Avenue Newton MA 02459	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-03-10	10,000	$4.75	565,122	No	4	M	Direct
Common Stock	Disposition	2020-03-10	7,932	$22.11	557,190	No	4	S	Direct
Common Stock	Disposition	2020-03-10	2,068	$22.64	555,122	No	4	S	Direct
Common Stock	Acquisiton	2020-03-09	10,000	$4.75	766,489	No	4	M	Indirect	By Spouse
Common Stock	Disposition	2020-03-09	7,000	$22.58	759,489	No	4	S	Indirect	By Spouse
Common Stock	Disposition	2020-03-09	3,000	$22.38	756,489	No	4	S	Indirect	By Spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Indirect	By Spouse
No	4	S	Indirect	By Spouse
No	4	S	Indirect	By Spouse

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-03-10	10,000	$0.00	10,000	$4.75
Common Stock	Stock Option (right to buy)	Disposition	2020-03-09	10,000	$0.00	10,000	$4.75

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
366,061		2023-09-02	No	4	M	Direct
410,303		2023-09-02	No	4	M	Indirect

Footnotes

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.57 to $22.55, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.575 to $22.76, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.095 to $23.04, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.05 to $23.75, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.